Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 9/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903856 | 0.94 | BTK (0.41) | ITKBTKFGFR3KDRAURKB | |
| SCHEMBL21903852 | 0.94 | BTK (0.41) | ITKBTKFGFR3KDRAURKB | |
| SCHEMBL21903891 | 0.92 | BTK (0.44) | IRAK1ITKBTK | |
| SCHEMBL24040170 | 0.91 | ITK (0.40) | ITKBTKMAPT | |
| SCHEMBL31684307 | 0.91 | ITK (0.40) | ITKBTKMAPT | |
| SCHEMBL21965633 | 0.90 | ITK (0.41) | ITKBTKUSP30 | |
| SCHEMBL31684277 | 0.90 | ITK (0.41) | ITKBTKUSP30 | |
| SCHEMBL21965595 | 0.90 | BTK (0.40) | ITKBTK | |
| SCHEMBL21965765 | 0.90 | ITK (0.40) | ITKBTKUSP30 | |
| SCHEMBL31684300 | 0.90 | BTK (0.40) | ITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180496-B2 | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-11-23 | — | — | US | disclosed |
| US-20200140432-A1 | NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180496-B2 | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same | PDCD11, DPYD, G6PC1 | IRAK1 516/4885ITK 409/4885BTK 1236/4885 |
| US-20200140432-A1 | NOVEL 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PDCD11, G6PC1, PPM1D | IRAK1 559/4885ITK 638/4885BTK 1744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.